Incyte Corp. (INCY)

86.14
1.28 1.51
NASDAQ : Health Technology
Prev Close 84.86
Open 84.88
Day Low/High 84.32 / 86.53
52 Wk Low/High 57.00 / 89.30
Volume 962.30K
Avg Volume 1.08M
Exchange NASDAQ
Shares Outstanding 215.40M
Market Cap 18.33B
EPS 0.50
P/E Ratio 45.51
Div & Yield N.A. (N.A)

Latest News

Incyte To Present At Upcoming Investor Conference

Incyte To Present At Upcoming Investor Conference

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the Credit Suisse 28 th Annual Healthcare Conference on Tuesday, November 12, 2019 at 8:35 am (MST) / 10:35 am (EST) in Scottsdale, Arizona.

Incyte Announces That The REACH2 Pivotal Trial Of Ruxolitinib (Jakafi®) Meets Primary Endpoint In Patients With Steroid-Refractory Acute Graft-Versus-Host Disease

Incyte Announces That The REACH2 Pivotal Trial Of Ruxolitinib (Jakafi®) Meets Primary Endpoint In Patients With Steroid-Refractory Acute Graft-Versus-Host Disease

Incyte Corporation (Nasdaq:INCY) today announced positive results from the Novartis-sponsored pivotal Phase 3 REACH2 study evaluating ruxolitinib (Jakafi ®) in patients with steroid-refractory acute graft-versus-host disease (GVHD).

Incyte Announces Positive 52-Week Results From A Randomized Phase 2 Study Of Ruxolitinib Cream In Patients With Vitiligo

Incyte Announces Positive 52-Week Results From A Randomized Phase 2 Study Of Ruxolitinib Cream In Patients With Vitiligo

Incyte (Nasdaq:INCY) today announces positive 52-week results from its randomized, double-blind, dose-ranging, Phase 2 study evaluating ruxolitinib cream, a nonsteroidal, anti-inflammatory, JAK inhibitor therapy, in adult patients with vitiligo.

Incyte To Report Third Quarter Financial Results

Incyte To Report Third Quarter Financial Results

Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its third quarter 2019 financial results conference call and webcast for 8:00 a.

Lilly To Unveil New Data For The Treatments Of Complex Dermatological Conditions At The 28th Annual European Academy Of Dermatology And Venereology (EADV) Congress

Lilly To Unveil New Data For The Treatments Of Complex Dermatological Conditions At The 28th Annual European Academy Of Dermatology And Venereology (EADV) Congress

Research from Taltz®, Olumiant® and mirikizumab highlight the impact Lilly's medicines may have for patients around the world

Incyte Announces Positive Updated Results From Phase 2 Trial Of Pemigatinib In Patients With Previously Treated, Advanced Cholangiocarcinoma

Incyte Announces Positive Updated Results From Phase 2 Trial Of Pemigatinib In Patients With Previously Treated, Advanced Cholangiocarcinoma

Incyte (Nasdaq:INCY) announces updated results, including the final result for the primary endpoint, from its Phase 2 FIGHT-202 trial evaluating pemigatinib, a selective fibroblast growth factor receptor (FGFR) inhibitor, as a treatment for patients with...

Incyte Announces First Patient Treated In Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream In Patients With Vitiligo

Incyte Announces First Patient Treated In Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream In Patients With Vitiligo

Incyte (Nasdaq:INCY) today announced that the first patient has been treated in the Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream as a monotherapy for adolescent and adult patients (age ≥12 years) with...

First Week Of INCY November 15th Options Trading

First Week Of INCY November 15th Options Trading

Investors in Incyte Corporation saw new options become available this week, for the November 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INCY options chain for the new November 15th contracts and identified one put and one call contract of particular interest.

Incyte To Host Investor Conference Call From ESMO 2019

Incyte To Host Investor Conference Call From ESMO 2019

Incyte (Nasdaq:INCY) announced today that it will host a conference call and webcast Friday, September 27, 2019, at 11:00 a.

Incyte Launches #MyMPNChallenge To Inspire The Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness Month

Incyte Launches #MyMPNChallenge To Inspire The Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness Month

Incyte (NASDAQ:INCY) is proud to further elevate awareness of myeloproliferative neoplasms (MPNs) throughout the month of September in honor of Blood Cancer Awareness Month and support the MPN community in recognizing MPN Awareness Day on September 12.

Data From Incyte's Oncology Portfolio To Be Featured At The 2019 ESMO Congress

Data From Incyte's Oncology Portfolio To Be Featured At The 2019 ESMO Congress

Incyte (Nasdaq:INCY) announces that abstracts highlighting data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain from September 27-October 1, 2019.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Lilly Announces Top-Line Phase 3 Results For Oral JAK Inhibitor Baricitinib, In Combination With Topical Corticosteroids In Adult Patients With Moderate To Severe Atopic Dermatitis

Lilly Announces Top-Line Phase 3 Results For Oral JAK Inhibitor Baricitinib, In Combination With Topical Corticosteroids In Adult Patients With Moderate To Severe Atopic Dermatitis

INDIANAPOLIS, Aug. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD7, the third pivotal Phase 3 trial in the BREEZE-AD program to be...

Incyte To Present At Upcoming Investor Conferences

Incyte To Present At Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: Morgan Stanley 17 th Annual Global Healthcare Conference on Tuesday, September 10, 2019 at 12:55 pm (EDT) in New...

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.

Incyte Reports 2019 Second Quarter Financial Results And Provides Updates On Key Clinical Programs

Incyte Reports 2019 Second Quarter Financial Results And Provides Updates On Key Clinical Programs

Incyte Corporation (Nasdaq:INCY) today reports 2019 second quarter financial results and provides a status update on the Company's development portfolio.

Incyte To Report Second Quarter Financial Results

Incyte To Report Second Quarter Financial Results

Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its second quarter 2019 financial results conference call and webcast for 8:00 a.

Http://www.zailaboratory.com

Http://www.zailaboratory.com

Incyte (NASDAQ:INCY) and Zai Lab Ltd. (NASDAQ:ZLAB) today announced that the companies have entered into a collaboration and license agreement for the development and commercialization of INCMGA0012, an investigational anti-PD-1 monoclonal antibody, in...

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

These two firms have successful drugs and could make nice additions for larger companies.

Incyte Announces Positive Results From A Phase 2 Study Of Ruxolitinib Cream In Patients With Vitiligo

Incyte Announces Positive Results From A Phase 2 Study Of Ruxolitinib Cream In Patients With Vitiligo

Incyte (Nasdaq:INCY) today announces 24-week results from its randomized, double-blind, dose-ranging, vehicle-controlled, Phase 2 study evaluating ruxolitinib cream, a nonsteroidal, anti-inflammatory, JAK inhibitor therapy, in adult patients (18 to 75...

Incyte Announces First Patient Treated In Phase 3 Clinical Trial Of Pemigatinib As A First-Line Therapy For Cholangiocarcinoma

Incyte Announces First Patient Treated In Phase 3 Clinical Trial Of Pemigatinib As A First-Line Therapy For Cholangiocarcinoma

Incyte (Nasdaq:INCY) today announced that the first patient has been treated in FIGHT-302, an open-label Phase 3 study evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, compared to gemcitabine with...

New Data From GEOMETRY Mono-1 Study Show Clinically Meaningful Results In Patients With Non-Small Cell Lung Cancer With MET Exon-14 Skipping Mutation Treated With Capmatinib

New Data From GEOMETRY Mono-1 Study Show Clinically Meaningful Results In Patients With Non-Small Cell Lung Cancer With MET Exon-14 Skipping Mutation Treated With Capmatinib

Incyte (Nasdaq:INCY) today announced primary efficacy results from the Novartis-sponsored GEOMETRY mono-1 Phase 2 clinical trial of capmatinib, an investigational, selective MET inhibitor.

FDA Approves Jakafi® (ruxolitinib) For The Treatment Of Patients With Acute Graft-Versus-Host Disease

FDA Approves Jakafi® (ruxolitinib) For The Treatment Of Patients With Acute Graft-Versus-Host Disease

Incyte Corporation (Nasdaq:INCY) today announced that the U.S.

Incyte To Present At Upcoming Investor Conference

Incyte To Present At Upcoming Investor Conference

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 40 th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019 at 2:00 pm (PDT) / 5:00 pm (EDT) in Rancho Palos Verdes.

Data From Incyte's Inflammation And Autoimmunity Portfolio To Be Featured At The 24th World Congress Of Dermatology

Data From Incyte's Inflammation And Autoimmunity Portfolio To Be Featured At The 24th World Congress Of Dermatology

Incyte Corporation (Nasdaq:INCY) announces that data from key studies within its inflammation and autoimmunity portfolio will be presented at the 24 th World Congress of Dermatology (WCD).

Incyte Announces Abstracts Accepted For Presentation At The 2019 ASCO Annual Meeting And The 24th Congress Of EHA

Incyte Announces Abstracts Accepted For Presentation At The 2019 ASCO Annual Meeting And The 24th Congress Of EHA

Incyte Corporation (Nasdaq:INCY) announces that multiple abstracts highlighting data from its oncology portfolio will be presented at the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 31-June 4, 2019, in...

Incyte To Present At Upcoming Investor Conferences

Incyte To Present At Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May: Bank of America Merrill Lynch Health Care Conference on Tuesday, May 14, 2019 at 8:40 am (PDT) in Las Vegas; UBS Global...

TheStreet Quant Rating: C+ (Hold)